Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01713959 · ClinicalTrials.gov registry record · NA
Feasibility Study: Ulthera® System for the Treatment of Axillary Hyperhidrosis
A NA study of Hyperhidrosis, sponsored by Ulthera.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01713959 is a NA study of Hyperhidrosis that has completed, run by Ulthera. The registered enrollment target is 15 participants, below the 97-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01713959, a NA study of Hyperhidrosis, has completed, sponsored by Ulthera.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Single-center, randomized, split-body, pilot study, treatment of up to 23 subjects in two treatment groups. Subjects will receive two Ultherapy treatments at Day 0 with follow-ups at 7 and 14 days post-treatment #1, and Day 28 with follow-ups are 7, 14, 30, 60, 90 days post-treatment #2.
Conditions Studied
Interventions
- DEVICE Sham treatment
- DEVICE Ulthera System treatment
Study Locations (1)
Florida
- The Center for Clinical & Cosmetic Research - Aventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01713959
The ClinicalTrials.gov registry entry for NCT01713959 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 8 other Hyperhidrosis trials with a reported enrollment target (85% lower). The listed sponsor is Ulthera, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hyperhidrosis appearing as the primary indexed condition, and to 2 interventions - of which Sham treatment is the first listed.
NCT01713959 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01713959 about?
NCT01713959 is a clinical study titled "Feasibility Study: Ulthera® System for the Treatment of Axillary Hyperhidrosis". Single-center, randomized, split-body, pilot study, treatment of up to 23 subjects in two treatment groups. Subjects will receive two Ultherapy treatments at Day 0 with follow-ups at 7 and 14 days post-treatment #1, and Day 28 with follow-ups are 7, 14, 30, 60, 90 days post-treatment #2.
What is the current status of trial NCT01713959?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2011-08. Estimated completion is 2012-06.
What conditions does trial NCT01713959 study?
This clinical trial studies the following conditions: Hyperhidrosis.
What interventions are being tested in trial NCT01713959?
The interventions under investigation include: Sham treatment (DEVICE), Ulthera System treatment (DEVICE).
Who is sponsoring clinical trial NCT01713959?
This trial is sponsored by Ulthera, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01713959 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperhidrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Botulinum Toxin Therapy in Hidradenitis Suppurativa
RECRUITING
-
Hyperhidrosis in Patients With Amputations-Botox
COMPLETED · Phase 1
-
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis
COMPLETED · Phase 2
-
Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis
COMPLETED · Phase 2
-
A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
COMPLETED · Phase 2
-
A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.